Item 8.01 Other Events.

On September 23, 2020, bluebird bio, Inc. ("bluebird") issued a press release announcing that its investigational treatment for sickle cell disease (SCD), LentiGlobin™ for SCD Gene Therapy (bb1111), was granted eligibility to the Priority Medicines (PRIME) program from the European Medicines Agency (EMA).

The full text of bluebird's press release is being furnished as Exhibit 99.1 to this Current Report on Form 8­K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
    Exhibit
      No.                                              Description
     99.1               Press release issued by bluebird bio, Inc. on September     2    3    ,
                      2020.
                      Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses